AstraZeneca Discloses Routine Share Sale by Non-Executive Director

AstraZeneca ( (GB:AZN) ) has provided an update.

AstraZeneca disclosed that non-executive director Nazneen Rahman sold 297 ordinary shares in the company at a price of £134.96 per share on 18 December 2025, in a transaction carried out on the London market and reported under UK market abuse regulations. The relatively small director share sale is a routine governance disclosure rather than a signal of a strategic shift, but it nonetheless provides transparency for investors monitoring insider dealings in one of the UK’s largest biopharmaceutical groups.

The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on GB:AZN Stock

According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.

AstraZeneca’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s strategic expansions and product approvals further enhance its outlook. However, the high valuation and moderate technical indicators slightly temper the overall score.

To see Spark’s full report on GB:AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focused on the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Average Trading Volume: 2,249,463

Technical Sentiment Signal: Strong Buy

Current Market Cap: £212B

For an in-depth examination of AZN stock, go to TipRanks’ Overview page.